Aldeyra Therapeutics (ALDX) director Deptula-Hicks submits initial Form 3

Rhea-AI Filing Summary

Aldeyra Therapeutics, Inc. director Darlene M. Deptula-Hicks filed an initial Form 3, which is a statement of beneficial ownership for insiders. This filing does not report any stock transactions or option exercises; it simply establishes her status as a reporting person at the company.

Key Terms

Form 3, reporting person, director

3 terms

Form 3 regulatory

"INSIDER FILING DATA (Form 3)"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

reporting person regulatory

""reportingPersons": [{"name": "DEPTULA-HICKS DARLENE M""

director regulatory

""is_director": 1"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding Insider Trading Forms →

Available on EDGAR 06/11/2026 - 04:13 PM Accepted by SEC EDGAR 06/11/2026 - 04:13 PM Learn about SEC filing dates

FAQ

What does the Aldeyra Therapeutics (ALDX) Form 3 filing show?

The Form 3 shows that Darlene M. Deptula-Hicks is a reporting person at Aldeyra Therapeutics as a director. It is an initial statement of beneficial ownership and does not list any stock transactions or derivative positions.

Did Darlene M. Deptula-Hicks buy or sell ALDX shares in this Form 3?

No, this Form 3 does not report any purchases or sales of ALDX shares. The transaction summary shows zero buy, sell, exercise, gift, tax-withholding, and restructuring transactions, indicating only an initial ownership filing.

What insider role is disclosed in the Aldeyra Therapeutics (ALDX) Form 3?

The filing identifies Darlene M. Deptula-Hicks as a director of Aldeyra Therapeutics. She is not listed as an officer or ten percent owner in this document, which focuses on her status as a reporting insider.

Are there any derivative securities reported in the ALDX Form 3?

No derivative securities are reported in this Form 3. The derivative summary section is empty and the transaction summary shows zero derivative transactions or exercises, indicating no options or similar instruments are listed here.

Does this Aldeyra Therapeutics (ALDX) Form 3 affect insider ownership totals?

The Form 3 formally records Darlene M. Deptula-Hicks as an insider but does not change ownership through new transactions. It contains no reported buys, sells, or option exercises, so it serves primarily as a baseline disclosure.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

DEPTULA-HICKS DARLENE M

(Last) (First) (Middle)

C/O ALDEYRA THERAPEUTICS, INC.

131 HARTWELL AVENUE

(Street)

LEXINGTON MASSACHUSETTS 02421

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
06/09/2026

3. Issuer Name and Ticker or Trading Symbol
Aldeyra Therapeutics, Inc. [ ALDX ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Darlene Deptula-Hicks	06/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)